Immunotherapy in the First-Line Setting in Wild-Type NSCLC.
Marie-Hélène DenaultBarbara MeloskyPublished in: Current oncology (Toronto, Ont.) (2021)
Treatment algorithms in the treatment of advanced non-small cell lung cancer (NSCLC) continue to evolve as new therapeutics show positive efficacy improvements. This review article summarizes the data for the use of immunotherapy for treatment in first-line stage IV NSCLC, organized by the following four sections: single-agent immunotherapy, immunotherapy and chemotherapy, dual immunotherapy, and dual immunotherapy and chemotherapy. The results are summarized and tabulated. Finally, application of the trial data is illustrated in four clinical scenarios depending on the programmed death-ligand 1 (PD-L1) expression levels. Single checkpoint inhibitors have become an easy and excellent treatment in patients whose tumors have high PD-L1 expression. Adding chemotherapy to immunotherapy benefits our patients. Immunotherapy, with or without chemotherapy, is now the standard of care in the first-line setting in patients without EGFR, ALK, or ROS driver mutations.
Keyphrases
- advanced non small cell lung cancer
- small cell lung cancer
- epidermal growth factor receptor
- end stage renal disease
- newly diagnosed
- locally advanced
- machine learning
- healthcare
- dna damage
- electronic health record
- prognostic factors
- climate change
- palliative care
- oxidative stress
- big data
- wild type
- randomized controlled trial
- cell cycle
- radiation therapy
- brain metastases
- tyrosine kinase
- patient reported outcomes
- cell proliferation
- combination therapy
- double blind